- Home
- GOSS vs GNLX Comparison
GOSS vs GNLX Comparison
Compare GOSS & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOSS | GNLX |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.2M | 113.6M |
| IPO Year | 2018 | 2022 |
Fundamental Metrics
Financial Performance| Metric | GOSS | GNLX |
|---|---|---|
| Price | $0.34 | $2.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $4.19 | ★ $19.80 |
| AVG Volume (30 Days) | ★ 10.5M | 162.5K |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,471,000.00 | $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $144.43 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.32 | $2.21 |
| 52 Week High | $3.87 | $8.54 |
Technical Indicators
Market Signals| Indicator | GOSS | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 28.06 | 50.44 |
| Support Level | $0.33 | $2.54 |
| Resistance Level | $0.60 | $3.00 |
| Average True Range (ATR) | 0.04 | 0.18 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 13.87 | 60.91 |
Price Performance
Historical ComparisonAbout GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.